BioLamina is a Sweden-based biotechnology company with a global presence, focused on matrix solutions for primary cell culture. The company offers a broad portfolio of full-length human recombinant laminin products for the efficient expansion of pluripotent cells, as well as the differentiation and maintenance of specialized cell types in physiologically relevant culture environments. Its Biolaminin® matrices are chemically defined and designed to support more biologically relevant cell–matrix interactions in vitro, including both 2D and 3D culture applications. BioLamina’s product portfolio highlights cell culture matrices, 3D culture solutions, and cell therapy grade products, and its full-length recombinant laminins are positioned as key extracellular matrix components for improving cell attachment, survival, proliferation, migration, organization, and specialization.
■ Product Portfolio
Vicbio Biotechnology Co., Ltd. provides the full range of BioLamina products.
⇨ Inquire or Order immediately ⇦
●Cell Culture Matrices
Almost all cells in the human body grow on specific laminins. With BioLamina’s full-length human recombinant laminin substrates, pluripotent stem cells, adult stem cells, and tissue-specific cells can be cultured in a physiologically relevant environment, including 3D culture settings. These defined matrices are designed to provide a more authentic extracellular environment and support improved cell functionality and more consistent cellular responses.
●3D Cell Culture
BioLamina’s 3D culture solutions, including Biosilk, provide a chemically defined 3D network that supports long-term cell survival without the need for cell encapsulation. These products can be used together with Biosilk or other 3D cell culture systems and combined with biologically relevant Biolaminin® matrices to help further enhance cell function in advanced culture models.
●Cell Therapy Grade Products
BioLamina’s cell therapy grade products are designed for clinical and translational applications and supported by comprehensive quality documentation. Its CTG products are developed for clinical cell applications, with extensive quality control, regulatory-oriented documentation, batch consistency, and animal-origin-free design to support cell therapy development workflows.
■ Product List
| Product name | Cat. # | Size |
| Biolaminin 521 LN (LN521) | LN521-02; LN521-05 | 100 µg; 500 µg |
| Biolaminin 521 MX (MX521) | MX521-0501 | 500 µg |
| Biolaminin 521 CTG (CT521) | CT521-0501 | 500 µg |
| Biolaminin 111 LN (LN111) | LN111-02; LN111-0501 | 100 µg; 500 µg |
| Biolaminin 121 LN (LN121) | LN121-02; LN121-0501 | 100 µg; 500 µg |
| Biolaminin 211 LN (LN211) | LN211-02; LN211-0501 | 100 µg; 500 µg |
| Biolaminin 221 LN (LN221) | LN221-02; LN221-0501 | 100 µg; 500 µg |
| Biolaminin 332 LN (LN332) | LN332-0202; LN332-0502 | 100 µg; 500 µg |
| Biolaminin 411 LN (LN411) | LN411-02; LN411-0501 | 100 µg; 500 µg |
| Biolaminin 421 LN (LN421) | LN421-02; LN421-0501 | 100 µg; 500 µg |
| Biolaminin 511 LN (LN511) | LN511-0202; LN511-0502 | 100 µg; 500 µg |
| Biosilk 521 | BS521-0101 | 812 μg |
| Biosilk | BS-0101 | 750 μg |
